Health Development Agency Delivery Plan 2003-06

This plan sets out the contribution the Health Development Agency (HDA) aims to make over the next three years to the cross-government objective of improving public health and reducing health inequalities. It reflects clear guidance given to the HDA by the minister for public health following the HDA۪s 2002 accountability review. The result is a smaller number of longer-term programmes fosused on four key delivery priorities: ۢ Underlying determinants of health ۢ The big killers coronary heart disease and cancer ۢ Children and young people ۢ Vulnerable adults

Analysis of the national childhood obesity database 2005-06

A report for the Department of Health by the South East Public Health Observatory on behalf of the Association of Public Health Observatories. The report looks at the first year of data collection on childhood obesity and the difficulties of this project. This report summarises the data available and provides high level analysis of the prevalence of overweight and obesity among the children measured in 2005-06.

Indicadores de desempeño educativo regional: metodología y resultados para los cursos 2005-06 a 2008-09

En este trabajo se construyen algunos indicadores de desempeño para los sistemas educativos no universitarios de las regiones españolas durante los cursos 2005-06 a 2008-09 a partir de información suministrada por diversas publicaciones del Ministerio de Educación. Estos indicadores permiten ofrecer respuestas a la pregunta de qué comunidades autónomas obtienen los mejores resultados educativos de acuerdo con una serie de criterios de desempeño definidos con claridad que recogen tanto aspectos de proceso (acceso a, éxito en y duración de los distintos ciclos educativos) como de resultados medidos en términos de la adquisición de conocimientos. Con el fin de poder hacer comparaciones válidas entre sistemas educativos que se enfrentan a circunstancias muy diversas, hemos construido también indicadores de valor añadido depurando los índices brutos de desempeño de los efectos de dos variables externas que tienen un fuerte impacto sobre los mismos: la disponibilidad de recursos económicos y el nivel educativo de las familias, aproximado por el número medio de años de escolarización de la población adulta.

A Multi-Center Phase II Study (SAKK 36/06) of Single Agent Everolimus (RAD001) In Patients with Relapsed or Refractory Mantle Cell Lymphoma

Introduction: Mantle cell lymphoma (MCL) accounts for 6% of all B-cell lymphomas and remains incurable for most patients. Those who relapse after first line therapy or hematopoietic stem cell transplantation have a dismal prognosis with short response duration after salvage therapy. On a molecular level, MCL is characterised by the translocation t[11;14] leading to Cyclin D1 overexpression. Cyclin D1 is downstream of the mammalian target of rapamycin (mTOR) kinase and can be effectively blocked by mTOR inhibitors such as temsirolimus. We set out to define the single agent activity of the orally available mTOR inhibitor everolimus (RAD001) in a prospective, multi-centre trial in patients with relapsed or refractory MCL (NCT00516412). The study was performed in collaboration with the EU-MCL network. Methods: Eligible patients with histologically/cytologically confirmed relapsed (not more than 3 prior lines of systemic treatment) or refractory MCL received everolimus 10 mg orally daily on day 1 - 28 of each cycle (4 weeks) for 6 cycles or until disease progression. The primary endpoint was the best objective response with adverse reactions, time to progression (TTP), time to treatment failure, response duration and molecular response as secondary endpoints. A response rate of 10% was considered uninteresting and, conversely, promising if 30%. The required sample size was 35 pts using the Simon's optimal two-stage design with 90% power and 5% significance. Results: A total of 36 patients with 35 evaluable patients from 19 centers were enrolled between August 2007 and January 2010. The median age was 69.4 years (range 40.1 to 84.9 years), with 22 males and 13 females. Thirty patients presented with relapsed and 5 with refractory MCL with a median of two prior therapies. Treatment was generally well tolerated with anemia (11%), thrombocytopenia (11%), neutropenia (8%), diarrhea (3%) and fatigue (3%) being the most frequent complications of CTC grade III or higher. Eighteen patients received 6 or more cycles of everolimus treatment. The objective response rate was 20% (95% CI: 8-37%) with 2 CR, 5 PR, 17 SD, and 11 PD. At a median follow-up of 6 months, TTP was 5.45 months (95% CI: 2.8-8.2 months) for the entire population and 10.6 months for the 18 patients receiving 6 or more cycles of treatment. Conclusion: This study demonstrates that single agent everolimus 10 mg once daily orally is well tolerated. The null hypothesis of inactivity could be rejected indicating a moderate anti-lymphoma activity in relapsed/refractory MCL. Further studies of either everolimus in combination with chemotherapy or as single agent for maintenance treatment are warranted in MCL.

State Library and Library Service Areas Plan of Service FY05-06

Vision: Each Iowans will have equal access to information and ideas in order to participate knowledgeably and productively in a democratic society and to lead an enriched life through lifelong learning. Mission: Helping libraries provide the best possible service to Iowans.

Motor Vehicle Division Quarterly Report on Building Project 3rd Quarter, FY 06

A quarterly report from the Iowa Department of Transportation regarding the Motor Vehicle Division building project status.

Annual Report of the Iowa Communications Network FY 06

This annual report covers highlights and financial information for fiscal year 2006 for the ICN. Any questions may be directed to Public Relations Manager Gail Geery.

Biodiesel Fuel Revolving Fund Expenditures Report, FY 06

Report of expenditures from the biodiesel fuel revolving fund for biodiesel fuel used in Iowa Department of Transportation vehicles.

Deaf Services Commission of Iowa Biennial Report for FY05-06, 2007

Division of Deaf Services Biennal Report for Fiscal Years 2005 and 2006, part of Department of Human Rights.

A Multi-Center Phase II Study (SAKK 36/06) of Single Agent Everolimus (RAD001) In Patients with Relapsed or Refractory Mantle Cell Lymphoma

Introduction: Mantle cell lymphoma (MCL) accounts for 6% of all B-cell lymphomas and remains incurable for most patients. Those who relapse after first line therapy or hematopoietic stem cell transplantation have a dismal prognosis with short response duration after salvage therapy. On a molecular level, MCL is characterised by the translocation t[11;14] leading to Cyclin D1 overexpression. Cyclin D1 is downstream of the mammalian target of rapamycin (mTOR) kinase and can be effectively blocked by mTOR inhibitors such as temsirolimus. We set out to define the single agent activity of the orally available mTOR inhibitor everolimus (RAD001) in a prospective, multi-centre trial in patients with relapsed or refractory MCL (NCT00516412). The study was performed in collaboration with the EU-MCL network. Methods: Eligible patients with histologically/cytologically confirmed relapsed (not more than 3 prior lines of systemic treatment) or refractory MCL received everolimus 10 mg orally daily on day 1 - 28 of each cycle (4 weeks) for 6 cycles or until disease progression. The primary endpoint was the best objective response with adverse reactions, time to progression (TTP), time to treatment failure, response duration and molecular response as secondary endpoints. A response rate of ≤ 10% was considered uninteresting and, conversely, promising if ≥ 30%. The required sample size was 35 pts using the Simon's optimal two-stage design with 90% power and 5% significance. Results: A total of 36 patients with 35 evaluable patients from 19 centers were enrolled between August 2007 and January 2010. The median age was 69.4 years (range 40.1 to 84.9 years), with 22 males and 13 females. Thirty patients presented with relapsed and 5 with refractory MCL with a median of two prior therapies. Treatment was generally well tolerated with anemia (11%), thrombocytopenia (11%), neutropenia (8%), diarrhea (3%) and fatigue (3%) being the most frequent complications of CTC grade III or higher. Eighteen patients received 6 or more cycles of everolimus treatment. The objective response rate was 20% (95% CI: 8-37%) with 2 CR, 5 PR, 17 SD, and 11 PD. At a median follow-up of 6 months, TTP was 5.45 months (95% CI: 2.8-8.2 months) for the entire population and 10.6 months for the 18 patients receiving 6 or more cycles of treatment. Conclusion: This study demonstrates that single agent everolimus 10 mg once daily orally is well tolerated. The null hypothesis of inactivity could be rejected indicating a moderate anti-lymphoma activity in relapsed/refractory MCL. Further studies of either everolimus in combination with chemotherapy or as single agent for maintenance treatment are warranted in MCL.

Informe preliminar del Crucero 6705 - 06 del otoño de 1967 (Cabo Blanco - Ilo)

Describe las actividades realizadas de acuerdo al plan operacional del año 1967 afín de determinar las condiciones físicas y químicas del mar así como la distribución de huevos y larvas de anchovetas y otros peces, la distribución de cardúmenes atribuibles a anchoveta y la distribución de aves guaneras.

Situación de los stocks de peces demersales en el otoño de 1990 : Crucero BIC SNP-l 9005-06 (19 de mayo - 08 de junio 1990) (Huarmey - Puerto Pizarro)

Analiza los resultados del crucero de evaluación de peces demersales con especial referencia a la merluza, para la plataforma continental comprendida entre la frontera con el Ecuador y 10º S, a profundidades entre 20 y 200 bz, totalizando 13542,27 millas náuticas cuadradas.